Stephanie Elliott
Family · Greencastle, INNPI 1144767526
Payments from drug & device makers
Across 94 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$388
- Novo Nordisk$187
- Ironshore Pharmaceuticals Inc.$150
- AstraZeneca$148
- Lilly USA, LLC$136
- Otsuka America Pharmaceutical, Inc.$113
- plus $687 from 18 others
What the payments were for
- Food & beverage$1,808100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 19 | $388 |
| Novo Nordisk | 9 | $187 |
| Ironshore Pharmaceuticals Inc. | 9 | $150 |
| AstraZeneca | 7 | $148 |
| Lilly USA, LLC | 8 | $136 |
| Otsuka America Pharmaceutical, Inc. | 6 | $113 |
| GSK | 5 | $82 |
| Corium, LLC | 5 | $68 |
| Amgen | 3 | $60 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Sanofi Pasteur Inc. | 2 | $46 |
| Exact Sciences | 2 | $44 |
| Merck | 2 | $44 |
| Ultragenyx Pharmaceutical Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Boehringer Ingelheim | 2 | $39 |
| Supernus Pharmaceuticals, Inc. | 1 | $30 |
| Ferring Pharmaceuticals Inc. | 1 | $29 |
| Abbott | 1 | $21 |
| Biogen | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Pfizer | 1 | $15 |
| Insulet Corporation | 1 | $11 |
How this compares
$1,808 in reported general payments places this provider in the 75th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 35 | $32,623 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $15,319 |
| TrulicityDulaglutide | 13 | $13,101 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $12,381 |
| GemtesaVibegron | 13 | $6,528 |
| Celecoxib | 14 | $924 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 34 | $725 |
| Levothyroxine Sodium | 88 | $646 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 44 | $605 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 13 | $504 |
| Duloxetine Hcl | 38 | $487 |
| Tamsulosin Hcl | 32 | $423 |
| Levocetirizine Dihydrochloride | 25 | $336 |
| Omeprazole | 41 | $333 |
| Olanzapine | 12 | $308 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $39 | $32,62335 claims |
| GSKTrelegy Ellipta | $82 | $15,31922 claims |
| Lilly USA, LLCTrulicity, Olanzapine | $136 | $13,40925 claims |
| AstraZenecaBreztri Aerosphere | $148 | $12,38111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,392 family providers in Indiana.
Other family in Greencastle
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.